(SEM) Select Medical Holdings - Overview
Stock: Hospitals, Rehabilitation, Clinics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.73% |
| Yield on Cost 5y | 1.84% |
| Yield CAGR 5y | -9.46% |
| Payout Consistency | 47.2% |
| Payout Ratio | 19.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 34.5% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -34.13 |
| Character TTM | |
|---|---|
| Beta | 0.756 |
| Beta Downside | 0.803 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.06% |
| CAGR/Max DD | 0.05 |
Description: SEM Select Medical Holdings January 16, 2026
Select Medical Holdings Corp. (NYSE: SEM) runs a network of critical-illness recovery hospitals, rehabilitation hospitals, and outpatient rehab clinics across the United States, organized into three segments: Critical Illness Recovery, Rehabilitation Hospital, and Outpatient Rehabilitation. The first segment treats patients with heart failure, respiratory failure, renal disease, neurological events and trauma; the second focuses on therapy for brain/spinal injuries, strokes, orthopedic and cancer-related conditions; the third delivers physical, occupational and speech services plus specialty programs such as hand therapy, pelvic health and post-concussion care.
In FY 2023 the company generated roughly $1.64 billion in revenue with an adjusted operating margin of about 7 %, and its critical-illness hospitals reported an average occupancy rate near 85 %. Growth is being driven by macro-level trends: an aging U.S. population increasing demand for post-acute care, expanding Medicare Advantage enrollment that favors bundled-payment models, and a sector-wide shift toward outpatient rehabilitation that improves cost efficiency and patient throughput.
For a deeper, data-rich perspective on SEM’s valuation dynamics, you might find ValueRay’s analyst toolkit worth exploring.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: 110.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.34 > 1.0 |
| NWC/Revenue: 2.06% < 20% (prev 2.62%; Δ -0.56% < -1%) |
| CFO/TA 0.07 > 3% & CFO 407.6m > Net Income 110.0m |
| Net Debt (971.5m) to EBITDA (232.7m): 4.17 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.5m) vs 12m ago -0.97% < -2% |
| Gross Margin: 8.24% > 18% (prev 0.13%; Δ 810.4% > 0.5%) |
| Asset Turnover: 57.47% > 50% (prev 75.60%; Δ -18.12% > 0%) |
| Interest Coverage Ratio: 1.12 > 6 (EBITDA TTM 232.7m / Interest Expense TTM 74.3m) |
Altman Z'' 0.88
| A: 0.01 (Total Current Assets 1.02b - Total Current Liabilities 939.6m) / Total Assets 5.69b |
| B: 0.15 (Retained Earnings 824.8m / Total Assets 5.69b) |
| C: 0.01 (EBIT TTM 82.9m / Avg Total Assets 6.84b) |
| D: 0.22 (Book Value of Equity 818.7m / Total Liabilities 3.67b) |
| Altman-Z'' Score: 0.88 = B |
Beneish M -2.66
| DSRI: 1.20 (Receivables 825.8m/1.06b, Revenue 3.93b/6.05b) |
| GMI: 1.61 (GM 8.24% / 13.22%) |
| AQI: 0.94 (AQ_t 0.50 / AQ_t-1 0.53) |
| SGI: 0.65 (Revenue 3.93b / 6.05b) |
| TATA: -0.05 (NI 110.0m - CFO 407.6m) / TA 5.69b) |
| Beneish M-Score: -2.66 (Cap -4..+1) = A |
What is the price of SEM shares?
Over the past week, the price has changed by +4.25%, over one month by +2.02%, over three months by +18.35% and over the past year by -18.28%.
Is SEM a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.4 | 17.3% |
| Analysts Target Price | 18.4 | 17.3% |
| ValueRay Target Price | 15.7 | -0.1% |
SEM Fundamental Data Overview February 03, 2026
P/E Forward = 12.3457
P/S = 0.3476
P/B = 1.0994
P/EG = 1.37
Revenue TTM = 3.93b USD
EBIT TTM = 82.9m USD
EBITDA TTM = 232.7m USD
Long Term Debt = 1.74b USD (from longTermDebt, last quarter)
Short Term Debt = 213.0m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 971.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.84b USD (1.87b + Debt 1.03b - CCE 60.1m)
Interest Coverage Ratio = 1.12 (Ebit TTM 82.9m / Interest Expense TTM 74.3m)
EV/FCF = 16.31x (Enterprise Value 2.84b / FCF TTM 174.0m)
FCF Yield = 6.13% (FCF TTM 174.0m / Enterprise Value 2.84b)
FCF Margin = 4.42% (FCF TTM 174.0m / Revenue TTM 3.93b)
Net Margin = 2.80% (Net Income TTM 110.0m / Revenue TTM 3.93b)
Gross Margin = 8.24% ((Revenue TTM 3.93b - Cost of Revenue TTM 3.61b) / Revenue TTM)
Gross Margin QoQ = 10.81% (prev 11.60%)
Tobins Q-Ratio = 0.50 (Enterprise Value 2.84b / Total Assets 5.69b)
Interest Expense / Debt = 2.90% (Interest Expense 29.9m / Debt 1.03b)
Taxrate = 21.01% (11.7m / 55.9m)
NOPAT = 65.5m (EBIT 82.9m * (1 - 21.01%))
Current Ratio = 1.09 (Total Current Assets 1.02b / Total Current Liabilities 939.6m)
Debt / Equity = 0.61 (Debt 1.03b / totalStockholderEquity, last quarter 1.69b)
Debt / EBITDA = 4.17 (Net Debt 971.5m / EBITDA 232.7m)
Debt / FCF = 5.58 (Net Debt 971.5m / FCF TTM 174.0m)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.61% (Net Income 110.0m / Total Assets 5.69b)
RoE = 6.51% (Net Income TTM 110.0m / Total Stockholder Equity 1.69b)
RoCE = 2.41% (EBIT 82.9m / Capital Employed (Equity 1.69b + L.T.Debt 1.74b))
RoIC = 1.88% (NOPAT 65.5m / Invested Capital 3.49b)
WACC = 6.42% (E(1.87b)/V(2.90b) * Re(8.70%) + D(1.03b)/V(2.90b) * Rd(2.90%) * (1-Tc(0.21)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.13%
[DCF Debug] Terminal Value 86.60% ; FCFF base≈245.4m ; Y1≈302.7m ; Y5≈515.6m
Fair Price DCF = 95.20 (EV 12.76b - Net Debt 971.5m = Equity 11.79b / Shares 123.8m; r=6.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -17.66 | EPS CAGR: -45.30% | SUE: -1.70 | # QB: 0
Revenue Correlation: -26.64 | Revenue CAGR: -3.52% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.44 | Chg30d=-0.002 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=1.31 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+6.4% | Growth Revenue=+4.3%